X

Trial Profile

Phase II Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabectedin (Primary) ; Dexamethasone; Dexamethasone; Ondansetron
Indications Chondrosarcoma; Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
Focus Therapeutic Use
Acronyms SYNERGIAS

Most Recent Events

24 Oct 2023 Results (n=33; From June/2021 to March/2023) assessing the QoL improvement and safety of Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients, presented at the 48th European Society for Medical Oncology Congress.
24 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com